| Literature DB >> 31635282 |
Gillian A M Tarr1, Taryn Stokowski2, Smriti Shringi3, Phillip I Tarr4, Stephen B Freedman5, Hanna N Oltean6, Peter M Rabinowitz7, Linda Chui8.
Abstract
Escherichia coli O157:H7 is the predominant cause of diarrhea-associated hemolytic uremic syndrome (HUS) worldwide. Its cardinal virulence traits are Shiga toxins, which are encoded by stx genes, the most common of which are stx1a, stx2a, and stx2c. The toxins these genes encode differ in their in vitro and experimental phenotypes, but the human population-level impact of these differences is poorly understood. Using Shiga toxin-encoding bacteriophage insertion typing and real-time polymerase chain reaction, we genotyped isolates from 936 E. coli O157:H7 cases and verified HUS status via chart review. We compared the HUS risk between isolates with stx2a and those with stx2a and another gene and estimated additive interaction of the stx genes. Adjusted for age and symptoms, the HUS incidence of E. coli O157:H7 containing stx2a alone was 4.4% greater (95% confidence interval (CI) -0.3%, 9.1%) than when it occurred with stx1a. When stx1a and stx2a occur together, the risk of HUS was 27.1% lower (95% CI -87.8%, -2.3%) than would be expected if interaction were not present. At the population level, temporal or geographic shifts toward these genotypes should be monitored, and stx genotype may be an important consideration in clinically predicting HUS among E. coli O157:H7 cases.Entities:
Keywords: Escherichia coli O157:H7; Shiga toxin-producing Escherichia coli; hemolytic uremic syndrome; stx genes
Year: 2019 PMID: 31635282 PMCID: PMC6832461 DOI: 10.3390/toxins11100607
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Characteristics of E. coli O157 cases by Shiga toxin genotype.
| Other ( | Overall ( | ||||
|---|---|---|---|---|---|
| Age (years) | |||||
| Median (IQR) | 18.0 (5.00, 42.5) | 11.0 (4.00, 30.0) | 12.0 (4.00, 33.0) | 23.0 (8.00, 46.8) | 16.0 (5.00, 39.3) |
| Comorbidity | |||||
| Present | 50 (11.4%) | 26 (11.6%) | 18 (9.5%) | 7 (8.5%) | 101 (10.8%) |
| Absent | 350 (79.7%) | 184 (81.8%) | 158 (83.2%) | 69 (84.1%) | 761 (81.3%) |
| Missing | 39 (8.9%) | 15 (6.7%) | 14 (7.4%) | 6 (7.3%) | 74 (7.9%) |
| Outbreak-related | |||||
| Yes | 42 (9.6%) | 32 (14.2%) | 14 (7.4%) | 1 (1.2%) | 89 (9.5%) |
| No | 397 (90.4%) | 193 (85.8%) | 176 (92.6%) | 81 (98.8%) | 847 (90.5%) |
| Diarrhea | |||||
| Present | 433 (98.6%) | 221 (98.2%) | 187 (98.4%) | 81 (98.8%) | 922 (98.5%) |
| Absent | 2 (0.5%) | 3 (1.3%) | 1 (0.5%) | 0 (0%) | 6 (0.6%) |
| Missing | 4 (0.9%) | 1 (0.4%) | 2 (1.1%) | 1 (1.2%) | 8 (0.9%) |
| Blood in stool | |||||
| Present | 398 (90.7%) | 189 (84.0%) | 161 (84.7%) | 61 (74.4%) | 809 (86.4%) |
| Absent | 31 (7.1%) | 32 (14.2%) | 22 (11.6%) | 20 (24.4%) | 105 (11.2%) |
| Missing | 10 (2.3%) | 4 (1.8%) | 7 (3.7%) | 1 (1.2%) | 22 (2.4%) |
| Vomiting | |||||
| Present | 204 (46.5%) | 121 (53.8%) | 102 (53.7%) | 28 (34.1%) | 455 (48.6%) |
| Absent | 223 (50.8%) | 103 (45.8%) | 82 (43.2%) | 52 (63.4%) | 460 (49.1%) |
| Missing | 12 (2.7%) | 1 (0.4%) | 6 (3.2%) | 2 (2.4%) | 21 (2.2%) |
| Abdominal pain | |||||
| Present | 408 (92.9%) | 204 (90.7%) | 175 (92.1%) | 71 (86.6%) | 858 (91.7%) |
| Absent | 16 (3.6%) | 13 (5.8%) | 8 (4.2%) | 8 (9.8%) | 45 (4.8%) |
| Missing | 15 (3.4%) | 8 (3.6%) | 7 (3.7%) | 3 (3.7%) | 33 (3.5%) |
| Fever | |||||
| Present | 167 (38.0%) | 78 (34.7%) | 70 (36.8%) | 20 (24.4%) | 335 (35.8%) |
| Absent | 245 (55.8%) | 132 (58.7%) | 107 (56.3%) | 53 (64.6%) | 537 (57.4%) |
| Missing | 27 (6.2%) | 15 (6.7%) | 13 (6.8%) | 9 (11.0%) | 64 (6.8%) |
| Hospitalized | |||||
| Yes | 167 (38.0%) | 93 (41.3%) | 85 (44.7%) | 20 (24.4%) | 365 (39.0%) |
| No | 263 (59.9%) | 130 (57.8%) | 105 (55.3%) | 60 (73.2%) | 558 (59.6%) |
| Missing | 9 (2.1%) | 2 (0.9%) | 0 (0%) | 2 (2.4%) | 13 (1.4%) |
| HUS | |||||
| Yes | 28 (6.4%) | 24 (10.7%) | 16 (8.4%) | 1 (1.2%) | 69 (7.4%) |
| No | 411 (93.6%) | 201 (89.3%) | 174 (91.6%) | 81 (98.8%) | 867 (92.6%) |
| RRT | |||||
| Yes | 11 (2.5%) | 14 (6.2%) | 10 (5.3%) | 1 (1.2%) | 36 (3.8%) |
| No | 428 (97.5%) | 211 (93.8%) | 180 (94.7%) | 81 (98.8%) | 900 (96.2%) |
Patient or caregiver reported presence of fever; if temperature was reported, fever was defined as ≥38.0 °C. ‘Other’ genotype includes stx1a-only, stx1a2a2c, stx1a2c, and stx2c-only genotypes. Abbreviations: HUS, hemolytic uremic syndrome; IQR, interquartile range; RRT, renal replacement therapy.
Figure 1Cumulative incidence of HUS by E. coli O157:H7 genotype. Error bars represent 95% exact binomial confidence intervals. Abbreviation: HUS, hemolytic uremic syndrome.
Excess risk of HUS due to stx2a vs. other genotypes.
| RD (95% CI) | RR (95% CI) | |||||
|---|---|---|---|---|---|---|
| Crude | Age-Adjusted | Fully Adjusted | Crude | Age-Adjusted | Fully Adjusted | |
|
| 0.043 | 0.036 | 0.044 | 1.67 | 1.52 | 1.58 |
|
| 0.022 | 0.021 | 0.03 | 1.27 | 1.24 | 1.43 |
| Other | 0.095 | 0.082 | 0.058 | 8.96 | 7.28 | 4.65 |
Fully adjusted models are adjusted for age, blood in stool, vomiting, and fever. Abbreviations: CI, confidence interval; HUS, hemolytic uremic syndrome; RD, risk difference; RR, relative risk.
Figure 2Directed acyclic graph of hypothesized relationships among stx genotype (exposure, green oval with triangle), HUS (outcome, blue oval with bar), and covariates. Age confounds the genotype-HUS relationship. There is a potential indirect pathway from genotype to HUS through symptoms (e.g., blood in stool, vomiting, fever) and clinical management (e.g., antibiotic use, intravenous fluid administration). Abbreviation: HUS, hemolytic uremic syndrome.